Alexion Pharmaceuticals (ALXN) PT Lowered to $186 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM EDTOppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following the company's announced top-line data from Phase 3 REGAIN study of eculizumab (Soliris) in refractory generalized myasthenia gravis (rGMG).
Analyst Christopher Marai commented, "Alexion announced... More
Alexion (ALXN) Buy On Weakness - Piper Jaffray
June 7, 2016 9:29 AM EDTPiper Jaffray analyst, Joshua Schimmer, noted that after the close, Alexion Pharmaceuticals (NASDAQ: ALXN) reported topline results from Phase 3 REGAIN study of Soliris for the treatment of refractory generalized myasthenia gravis. While the study failed to meet the primary efficacy endpoint of change from baseline... More
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM EDTBMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing data from the Phase III trial of Soliris in Myasthenia Gravis (MG). Although the totality of the data suggests significant benefit, the study missed its primary endpoint... More
Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical Significance
June 6, 2016 4:03 PM EDTAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG - a debilitating, complement-mediated neuromuscular disease - in which... More
